The earnings call reflects a challenging year for BICO with several operational improvements leading to a stronger EBITDA margin and a solid cash position. However, the company faced significant hurdles with negative sales growth, particularly in Lab Automation and the Chinese market. Despite these challenges, BICO is well-positioned with improved operational efficiencies and a strong cash flow, but the overall sales outlook remains cautious.
Company Guidance
During BICO's 2024 Year-End Earnings Call, Maria Forss, CEO, and Jacob Thordenberg, CFO, provided comprehensive guidance on the company's financial performance. They noted that BICO's revenue for Q4 2024 stood at SEK571 million, maintaining parity with the same quarter in 2023 and reflecting a slight negative organic growth of 0.3%. The adjusted EBITDA margin improved significantly, reaching 25%, a 12 percentage point increase from the previous year. The company ended the year with a robust cash position of SEK946 million, later adjusted to SEK699 million following a bond buyback. Despite a challenging market characterized by CapEx constraints and weak demand from China, BICO achieved double-digit EBITDA margins across all business areas, driven by operational excellence and cost control. The Lab Automation segment faced fewer project starts, affecting its sales, while Life Science Solutions and Bioprinting demonstrated resilience with positive seasonal effects and demand for consumables. BICO also divested Nanoscribe, enhancing its cash flow by SEK251 million, and reduced convertible debt to SEK1.1 billion. For 2025, BICO aims to execute its BICO 2.0 strategy, focusing on commercial initiatives and operational excellence to navigate ongoing market uncertainties.
Improved EBITDA Margin
Adjusted EBITDA margin improved to 25% in Q4 2024, representing a 12 percentage point increase compared to the same quarter last year.
Strong Cash Position
Finished the year with a strong cash position of SEK946 million, or SEK699 million after buybacks, indicating financial stability.
Operational Excellence Initiatives
Significant steps taken to improve cash flow, including divestment of loss-making units and working capital improvements.
Positive Trends in Life Science Solutions
Life Science Solutions showed a 7% organic growth in Q4, aided by seasonal effects and operational excellence activities.
---
BICO Group AB Class B (CLLKF) Earnings, Revenues Date & History
The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
CLLKF Earnings-Related Price Changes
Report Date
Price 1 Day Before
Price 1 Day After
Percentage Change
Feb 19, 2025
$3.50
$3.98
+13.71%
Nov 26, 2024
$3.36
$2.76
-17.86%
Aug 20, 2024
$4.20
$4.05
-3.57%
May 07, 2024
$4.18
$3.64
-12.92%
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does BICO Group AB Class B (CLLKF) report earnings?
BICO Group AB Class B (CLLKF) is schdueled to report earning on Apr 29, 2025, TBA Not Confirmed.
What is BICO Group AB Class B (CLLKF) earnings time?
BICO Group AB Class B (CLLKF) earnings time is at Apr 29, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.